Research Analysts Set Expectations for PTCT FY2025 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – William Blair lowered their FY2025 earnings estimates for shares of PTC Therapeutics in a report issued on Monday, July 14th. William Blair analyst S. Corwin now anticipates that the biopharmaceutical company will earn $6.14 per share for the year, down from their prior forecast of $6.38. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

Several other research analysts have also issued reports on PTCT. Citigroup raised shares of PTC Therapeutics from a “sell” rating to a “neutral” rating and reduced their target price for the company from $50.00 to $40.00 in a research note on Wednesday, May 7th. Cantor Fitzgerald reduced their target price on shares of PTC Therapeutics from $113.00 to $112.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Barclays reduced their target price on shares of PTC Therapeutics from $56.00 to $42.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 8th. Royal Bank Of Canada raised their target price on shares of PTC Therapeutics from $57.00 to $58.00 and gave the company an “outperform” rating in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. reduced their target price on shares of PTC Therapeutics from $75.00 to $67.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, PTC Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $65.00.

PTC Therapeutics Stock Down 3.5%

Shares of NASDAQ:PTCT opened at $47.75 on Tuesday. The firm has a market cap of $3.78 billion, a P/E ratio of 7.33 and a beta of 0.50. PTC Therapeutics has a 12 month low of $29.02 and a 12 month high of $58.38. The company’s 50-day moving average price is $48.49 and its two-hundred day moving average price is $48.44.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $9.19. PTC Therapeutics had a net margin of 33.56% and a negative return on equity of 78.56%. The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $437.16 million. During the same quarter in the prior year, the firm earned ($1.20) EPS. The company’s revenue was down 9.6% on a year-over-year basis.

Insider Activity at PTC Therapeutics

In other news, CEO Matthew B. Klein sold 2,804 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $48.74, for a total value of $136,666.96. Following the sale, the chief executive officer directly owned 273,234 shares in the company, valued at $13,317,425.16. This trade represents a 1.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mark Elliott Boulding sold 883 shares of PTC Therapeutics stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $46.02, for a total transaction of $40,635.66. Following the completion of the sale, the vice president owned 103,901 shares in the company, valued at $4,781,524.02. This trade represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,616 shares of company stock worth $266,384 over the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On PTC Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of PTC Therapeutics by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company’s stock valued at $414,332,000 after buying an additional 53,688 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of PTC Therapeutics by 13.2% in the first quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company’s stock valued at $276,161,000 after buying an additional 632,049 shares in the last quarter. Toronto Dominion Bank bought a new position in shares of PTC Therapeutics in the fourth quarter valued at $148,363,000. Janus Henderson Group PLC grew its stake in shares of PTC Therapeutics by 24.4% in the fourth quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company’s stock valued at $105,015,000 after buying an additional 455,698 shares in the last quarter. Finally, Driehaus Capital Management LLC boosted its position in PTC Therapeutics by 45.3% during the first quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company’s stock worth $77,084,000 after purchasing an additional 471,586 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.